These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 21247998)
41. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251 [TBL] [Abstract][Full Text] [Related]
42. Preliminary Evidence for cue-induced Alcohol Craving Modulated by Serotonin Transporter Gene Polymorphism rs1042173. Ait-Daoud N; Seneviratne C; Smith JB; Roache JD; Dawes MA; Liu L; Wang XQ; Johnson BA Front Psychiatry; 2012; 3():6. PubMed ID: 22355291 [TBL] [Abstract][Full Text] [Related]
43. Study suggests gene may predict success of therapies for alcohol dependence. Kuehn BM JAMA; 2011 Mar; 305(10):984-5. PubMed ID: 21386072 [No Abstract] [Full Text] [Related]
44. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071 [TBL] [Abstract][Full Text] [Related]
45. Association, interaction, and replication analysis of genes encoding serotonin transporter and 5-HT3 receptor subunits A and B in alcohol dependence. Seneviratne C; Franklin J; Beckett K; Ma JZ; Ait-Daoud N; Payne TJ; Johnson BA; Li MD Hum Genet; 2013 Oct; 132(10):1165-76. PubMed ID: 23757001 [TBL] [Abstract][Full Text] [Related]
46. A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil. Corrêa Filho JM; Baltieri DA Addict Behav; 2013 Apr; 38(4):2044-51. PubMed ID: 23396176 [TBL] [Abstract][Full Text] [Related]
47. Clinical pharmacology of serotonin-altering medications for decreasing alcohol consumption. Naranjo CA; Bremner KE Alcohol Alcohol Suppl; 1993; 2():221-9. PubMed ID: 7748304 [TBL] [Abstract][Full Text] [Related]
48. Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes. Johnson B; Alho H; Addolorato G; Lesch OM; Chick J; Liu L; Schuyler V Eur J Intern Med; 2024 Jun; ():. PubMed ID: 38876929 [TBL] [Abstract][Full Text] [Related]
49. Variation in the gene encoding the serotonin transporter is associated with a measure of sociopathy in alcoholics. Herman AI; Conner TS; Anton RF; Gelernter J; Kranzler HR; Covault J Addict Biol; 2011 Jan; 16(1):124-32. PubMed ID: 20192950 [TBL] [Abstract][Full Text] [Related]
50. A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Wong CJ; Witcher J; Mallinckrodt C; Dean RA; Anton RF; Chen Y; Fijal BA; Ouyang H; Dharia S; Sundseth SS; Schuh KJ; Kinon BJ Alcohol Clin Exp Res; 2014 Feb; 38(2):511-20. PubMed ID: 24010675 [TBL] [Abstract][Full Text] [Related]
51. Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse. Lynch WJ; Bond C; Breslin FJ; Johnson BA Psychopharmacology (Berl); 2011 Sep; 217(1):3-12. PubMed ID: 21424693 [TBL] [Abstract][Full Text] [Related]
53. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. Falk DE; Ryan ML; Fertig JB; Devine EG; Cruz R; Brown ES; Burns H; Salloum IM; Newport DJ; Mendelson J; Galloway G; Kampman K; Brooks C; Green AI; Brunette MF; Rosenthal RN; Dunn KE; Strain EC; Ray L; Shoptaw S; Ait-Daoud Tiouririne N; Gunderson EW; Ransom J; Scott C; Leggio L; Caras S; Mason BJ; Litten RZ; Alcohol Clin Exp Res; 2019 Jan; 43(1):158-169. PubMed ID: 30403402 [TBL] [Abstract][Full Text] [Related]
54. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. O'Malley SS; Corbin WR; Leeman RF; DeMartini KS; Fucito LM; Ikomi J; Romano DM; Wu R; Toll BA; Sher KJ; Gueorguieva R; Kranzler HR J Clin Psychiatry; 2015 Feb; 76(2):e207-13. PubMed ID: 25742208 [TBL] [Abstract][Full Text] [Related]
55. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Faris PL; Kim SW; Meller WH; Goodale RL; Oakman SA; Hofbauer RD; Marshall AM; Daughters RS; Banerjee-Stevens D; Eckert ED; Hartman BK Lancet; 2000 Mar; 355(9206):792-7. PubMed ID: 10711927 [TBL] [Abstract][Full Text] [Related]
56. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Myrick H; Anton RF; Li X; Henderson S; Randall PK; Voronin K Arch Gen Psychiatry; 2008 Apr; 65(4):466-75. PubMed ID: 18391135 [TBL] [Abstract][Full Text] [Related]
57. Serotonin transporter promoter polymorphism genotype is associated with behavioral disinhibition and negative affect in children of alcoholics. Twitchell GR; Hanna GL; Cook EH; Stoltenberg SF; Fitzgerald And HE; Zucker RA Alcohol Clin Exp Res; 2001 Jul; 25(7):953-9. PubMed ID: 11505018 [TBL] [Abstract][Full Text] [Related]
58. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Sellers EM; Toneatto T; Romach MK; Somer GR; Sobell LC; Sobell MB Alcohol Clin Exp Res; 1994 Aug; 18(4):879-85. PubMed ID: 7978099 [TBL] [Abstract][Full Text] [Related]
59. Serotonergic agents and alcoholism treatment: a simulation. Stoltenberg SF Alcohol Clin Exp Res; 2003 Dec; 27(12):1853-9. PubMed ID: 14691371 [TBL] [Abstract][Full Text] [Related]